Kanjin Therapeutics

Private

DelawareHealthcare & Life Scienceshttps://kanjin-tx.com

Last Round

Seed

Apr 27, 2026

Total Funding Raised

$330,000

Company Overview

Kanjin Therapeutics is a biotechnology company developing advanced therapeutics to halt and potentially restore kidney function, with the goal of eliminating the need for dialysis.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

chronic kidney diseaseCKDpre-clinical biotechdrug discoverydrug developmentnephrologybiotechnologynovel drug targetbiopharmapharmaceutical licensingrenal dysfunctionuniversity spinouttranslational science

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Kanjin Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Kanjin Therapeutics comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Kanjin Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Seed	Apr 27, 2026

View all Funding Rounds

Key People

Founding team and executive leadership

Caleb Bell

Co-Founder and CEO

Founding Team

Kanjin Therapeutics Investors

Notable investors and investment history

Kanjin Therapeutics investors
Investor	Rounds
Kyoto University Innovation Capital	Seed

View all Investors

Kanjin Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Kanjin Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Kanjin Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersDelaware

Employee Range3

Year Founded2025

Last FundingApr 27, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.